Last updated on August 2018

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF


Brief description of study

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Clinical Study Identifier: NCT03547583

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Groote Schuur Hospital
Cape Town, South Africa
  Connect »

Bayer Clinical Trials Contact

Tiervlei Trial Centre
Cape Town, South Africa
2.89miles
  Connect »

Bayer Clinical Trials Contact

TREAD Research cc
Cape Town, South Africa
7.44miles
  Connect »